Ob/Gyn Updated
286 FOLLOWERS
Your Web destination for the latest in Evidence based Obstetrics, Gynecology and Women’s health.
Ob/Gyn Updated
5y ago
This June 18, 2019 photo provided by the Cleveland Clinic Cleveland Clinic in Ohio becomes the first hospital in North America to deliver a baby born out of uterus that was transplanted after the donor was deceased. The mother, who is in her mid-30s, is part of a groundbreaking research trial involving 10 women with uterine factor infertility, who are all destined to receive uterus from deceased donors. Since the start of the trial, the team has performed 5 uterine transplants, of which 3 were successful, including the one which resulted in a live birth. Two other women are waiting for emb ..read more
Ob/Gyn Updated
5y ago
courtesy: APT The U.S. Food and Drug Administration (FDA) granted a Breakthrough Device Designation for the Advanced Prenatal Therapeutics, Inc. (APT) Targeted Apheresis Column for Preeclampsia (TAC-PE) in the treatment of preeclampsia. Currently, the therapeutic options for preeclampsia are limited and include bed rest, anti-hypertensive medications and induction of preterm labor if needed. The TAC-PE column is an apheresis device that works like kidney dialysis in selectively removing the harmful substances from the blood. While the exact cause of preeclampsia is not known, several biomarke ..read more
Ob/Gyn Updated
5y ago
Courtesy: AMAG Pharmaceuticals The US Food and Drug Administration (FDA) recently approved bremelanotide (Vyleesi, AMAG Pharmaceuticals), for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Vyleesi, a melanocortin receptor agonist that comes as autoinjector, joins flibanserin(Addyi, Sprout Pharmaceuticals) as the class of drugs approved by the FDA for the treatment of acquired HSDD. Flibanserin is Serotonin 5-HT-Receptor Agonists and is taken orally. HSDD is the most commonly prevalent female sexual dysfunction and is largely under-recognized and undertrea ..read more
Ob/Gyn Updated
6y ago
The American College of Obstetricians and Gynecologists (ACOG) now recommends Letrozole (aromatase inhibitor) as the first-line treatment for ovulation induction in women with Polycystic Ovarian Syndrome (PCOS) due to data demonstrating increased ovulation rates, clinical pregnancy rates and live-birth rate vs clomiphene citrate. The guidelines are published as Practice Bulletin No. 194 in the June issue of Journal Obstetrics and Gynecology. This replaces the Practice Bulletin Number 108, published October 2009, which recommends letrozole as first-line therapy for ovulation induction only in ..read more